Excelsior Biopharma Inc

Excelsior Biopharma Inc

TTPEX:6496
22.05
TWD
-1.35
(-5.77%)
-3.99EPS
1.10BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
24.81
26.98
29.13
32.95
36.76
36.2
33
30.94
28.78
14.39
16.8
18.69
19.46
20.74
Basic EPS, GAAP
4.08
3.62
3.37
3.87
5.99
4.75
1.52
0.76
-0.34
-0.72
-1.98
-2.14
-3.97
-3.99
Free Cash Flow per Basic Share
2.74
2.58
0.04
3.82
7.13
2.52
-4.07
10.91
1.14
-0.05
-3.71
-7.74
-3.81
-2.19
Dividend per Share
1.3
2.4
2.5
2.5
4
4
4
1
1
- -
- -
- -
- -
- -
Book Value per Share
16.36
17.68
19.34
26.73
28.71
29.43
26.89
27.49
26.83
25.86
23.51
21.21
17.27
14.12
Tangible Book Value per Share
16.36
17.68
19.34
26.73
28.71
29.42
26.89
27.49
26.83
25.86
23.51
21.21
17.27
14.12
Basic Weighted Avg Shares
38
43
43
47
47
47
47
47
47
47
46
46
46
46
Sales/Revenue/Turnover
954
1,147
1,238
1,535
1,716
1,689
1,540
1,444
1,338
672
772
862
898
960
Operating Margin (%)
18.53
17.08
14.14
14.04
18.99
16.69
5.57
2.83
-0.32
-4.91
-10.39
-9.13
-19.39
-18.28
Depreciation Expense
15
22
22
24
25
25
29
27
29
26
46
71
72
70
Net Income, GAAP
157
154
143
180
280
222
71
35
-16
-34
-91
-99
-183
-185
Effective Tax Rate (%)
19.06
21
19.11
17.46
16.94
22.42
22.66
22.07
- -
- -
- -
- -
- -
- -
Profit Margin (%)
16.45
13.42
11.58
11.76
16.3
13.13
4.61
2.45
-1.17
-5.03
-11.8
-11.45
-20.39
-19.24
Working Capital
505
574
645
1,070
1,156
1,194
1,039
1,374
1,282
984
818
548
355
217
LT Debt
- -
- -
- -
- -
- -
- -
75
361
351
43
300
356
302
282
Total Equity
695
751
822
1,247
1,340
1,373
1,255
1,283
1,230
1,207
1,104
991
804
658
Return on Invested Capital (%)
20.58
19.59
16.29
15.9
19.49
15.28
4.81
2.12
- -
- -
- -
- -
- -
- -
Return on Capital (%)
25.04
20.05
16.86
16.44
20.65
15.93
5.24
2.43
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
24.15
21.28
18.22
17.44
21.62
16.35
5.4
2.78
-1.25
-2.77
-7.87
-9.42
-20.4
- -

Capital Structure

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
222
273
275
LT Borrowings
110
109
107
LT Finance Leases
180
167
175
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
47
47
Market Capitalization
1,260
1,178
1,102

Working Capital

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
692
694
691
Cash, Cash Equivalents & STI
131
141
118
Accounts Receivable, Net
201
191
200
Inventories
332
328
354
Total Current Liabilities
388
447
475
Payables & Accruals
- -
- -
- -
ST Debt
222
273
275
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.17%
-8.72%
-18.88%
Free Cash Flow
1,750.53%
1,436.68%
-50.79%
Net Income, GAAP
17.69%
47%
85.57%
Sales/Revenue/Turnover
-0.72%
-5.26%
4.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
190
213
218
241
862
2025
210
202
- -
279
898
2026
218
232
230
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.73
-0.46
-0.48
-0.47
-2.14
2025
-0.89
-1.03
- -
-0.85
-3.97
2026
-1.18
-1.24
-0.72
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Tse Min Chen
Full Time Employees
15
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 508, Zhongxiao E. Rd. Taipei TPE Taiwan 11561
IPO Date
Dec 19, 2014
Business
Excelsior Biopharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan, China, and internationally. The company offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and other products for therapeutic areas including pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, otorhinolaryngology, and infectious diseases; test kits under the Actim brand to detect influenza virus, fecal occult blood, acute pancreatitis, preterm or full-week delivery, and early water breaking; toothpaste, mouthwash, and gel products under the Oral7 brand; food and medical beauty maintenance products; and imports and exports active pharmaceutical ingredients while engaging in pharmaceutical technology research, transfer, cooperative development, and improvement activities. Incorporated in 1988 and headquartered in Taipei, Taiwan, the company operates primarily in the healthcare sector, targeting hospitals, clinics, and consumers with a focus on rare and niche specialty diseases across Southeast Asia through subsidiaries such as Excelsior Biotech (Malaysia) SDN. BHD., established in February 2020. Formerly known as Excelsior Enterprise Co., Ltd., it changed its name to Excelsior Biopharma Inc. in June 2003; recent activities include advancing a preclinical pipeline featuring Agalsidase alfa for Fabry Disease, EX-054 for lysosomal storage diseases, and TGF-β-targeted candidates like EX042-002 series for fibrosis, Alzheimer's disease, and neoplasms, alongside ongoing ESG initiatives such as establishing the Excelsior Fellowship Activity Center in 2025 for rare disease patient support and participation in pulmonary hypertension education events.